(April.2010-March.2015)

Determination for the Real Growth

Basic Strategy 1 : Steady Growth Mainly through Enriched Pipeline

Domestic Sales

• The Company will focus its sales and marketing resources on 3 key strategic products, Crestor, Irbetan and Cymbalta, and other 5 new products
• More than 70% of net sales generated by 8 new products
• From legacy product dependant to newer product dependent growth

Overseas business

• The Company will expand consolidated overseas net sales ratio excluding  royalty to approximately 30% by consistently promoting marketed and products in development

Basic Strategy 2 : Investments in the New Growth Drivers

• Globally develop more than 5 products in the late stage (Ph 2b and beyond)
• Achieve NDA submission overseas for 4 products (originate from Shionogi or Japanese research institutes), and launch of more than one product by FY2014

Basic Strategy 3 : Therapeutic Areas to Be Focused on

• The Company will continue to provide patients with medicines to treat metabolic syndrome, infectious diseases and pain. It will also focus management resources specially on obesity/diabetes and viral infection positioned as R&D priority areas

Globalization during the 3rd Medium-Term Business Plan

• Establish footholds in EU, USA and Asia for global development of new drugs
• Establish aggressively a business platform in Asia aiming for direct sales
• Select multiple alliance partners in EU for sales

Financial Target for FY2014(Consolidation)

Strengthening of Operational Fundamentals and Shareholder Return

Put 3 Gears in Motion and Implement Both Strengthening of a Business Foundation and Shareholder Return While Balancing the Two Well